Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | ATF4 | P18848 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21116605 | 0.92 | ADAMTS5 (0.43) | ALDH1A1ATF4LMNASMN1; SMN2GAA | |
| SCHEMBL24323059 | 0.90 | GAA (0.53) | L3MBTL1ALDH1A1ATF4LMNAGAA | |
| SCHEMBL24322876 | 0.90 | ATF4 (0.45) | ALDH1A1ATF4LMNASMN1; SMN2GAA | |
| SCHEMBL24324507 | 0.90 | LMNA (0.49) | ALDH1A1ATF4LMNASMN1; SMN2GAA | |
| SCHEMBL21116655 | 0.88 | TRPV1 (0.44) | EPHX2ALDH1A1ATF4LMNASMN1; SMN2 | |
| SCHEMBL24116960 | 0.88 | TAOK1 (0.51) | ALDH1A1ATF4SMN1; SMN2 | |
| SCHEMBL21117004 | 0.88 | KMT2A (0.47) | L3MBTL1ALDH1A1ATF4SMN1; SMN2 | |
| SCHEMBL21116606 | 0.87 | ATF4 (0.45) | ALDH1A1ATF4LMNASMN1; SMN2GAA | |
| SCHEMBL24116642 | 0.86 | ALDH1A1 (0.47) | EPHX2ALDH1A1ATF4LMNASMN1; SMN2 | |
| SCHEMBL21116431 | 0.86 | PTPRZ1 (0.42) | EPHX2NR1H4ALDH1A1ATF4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10836725-B2 | Modulators of the integrated stress pathway | ABBVIE INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-20190194135-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10836725-B2 | Modulators of the integrated stress pathway | ATF4, ATF1, DDIT3 | L3MBTL1 1651/4885EPHX2 3932/4885NR1H4 747/4885 |
| US-20190194135-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | L3MBTL1 1651/4885EPHX2 3932/4885NR1H4 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.